This section highlights FDA-related milestones and regulatory updates for drugs developed by GE HealthCare Technologies (GEHC).
Over the past two years, GE HealthCare Technologies has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
mangaciclanol, Vizamyl, and Cerianna. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
Mangaciclanol FDA Regulatory Events
Mangaciclanol is a drug developed by GE HealthCare Technologies for the following indication: magnetic resonance imaging (MRI) contrast agent (MBCA).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- mangaciclanol
- Announced Date:
- November 19, 2026
- Indication:
- magnetic resonance imaging (MRI) contrast agent (MBCA)
Announcement
GE HealthCare announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA).
AI Summary
GE HealthCare said Phase 2 results from its international, multicenter LUMINA trial support moving mangaciclanol into Phase 3, with a dose of 0.1 mmol/kg selected. Mangaciclanol is an investigational manganese-based MRI contrast agent. The adaptive Phase 2/3 study enrolled adults with known or suspected lesions who were referred for contrast-enhanced MRI of the central nervous system.
Participants received both mangaciclanol and gadobutrol, a commonly used gadolinium-based agent. Blinded independent readers compared the images side by side. The trial met its primary endpoint: overall diagnostic preference was similar for the two agents. Lesion visualization and quantitative imaging results were also generally similar. Mangaciclanol was well tolerated in Phase 2, and no safety concerns were identified after administration; safety will continue to be assessed in Phase 3.
Phase 3 will further assess mangaciclanol’s efficacy and safety for detecting and characterizing lesions in the central nervous system and body. The study is being conducted at sites in the United States, Europe, and Asia.
Read Announcement
Vizamyl FDA Regulatory Events
Vizamyl is a drug developed by GE HealthCare Technologies for the following indication: For beta-amyloid detection.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Vizamyl
- Announced Date:
- June 24, 2025
- Indication:
- For beta-amyloid detection.
Announcement
GE HealthCare announced that the U.S. Food and Drug Administration (FDA) has approved an updated label for its positron emission tomography (PET) imaging agent VizamylTM (flutemetamol F 18 injection) for beta-amyloid detection.
AI Summary
GE HealthCare announced that the U.S. FDA approved an updated label for its PET imaging agent Vizamyl (flutemetamol F 18 injection) used for beta-amyloid detection. The new label now includes a quantification feature that allows clinicians to measure the level of amyloid plaques in the brain more accurately, using dedicated software to calculate amyloid load. This updated approach offers a more objective assessment compared to the previous visual-only method.
Additionally, the label change expands Vizamyl’s use, enabling healthcare providers to monitor patient responses to anti-amyloid therapies. This helps in determining when treatment can be adjusted or stopped based on changes in plaque density. Overall, the FDA’s update supports clearer diagnoses and more personalized treatment strategies for Alzheimer’s disease and related cognitive impairments.
Read Announcement
Cerianna FDA Regulatory Events
Cerianna is a drug developed by GE HealthCare Technologies for the following indication: For Lobular Breast Cancer.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Cerianna
- Announced Date:
- May 30, 2025
- Indication:
- For Lobular Breast Cancer
Announcement
GE HealthCare announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer.
AI Summary
GE HealthCare announced that the NCCN Guidelines® now recommend using fluoroestradiol (FES) PET for systemic staging in patients with recurrent or metastatic lobular breast cancer. This update highlights GE HealthCare’s Cerianna™ (fluoroestradiol F18) injection—currently the only FDA-approved imaging agent for detecting estrogen receptor positive (ER+) lesions in breast cancer. The recommendation is important because lobular breast cancer is often hard to detect with standard imaging, and it can recur in unexpected places, such as the bones or liver. With FES PET, clinicians may achieve greater diagnostic accuracy, which can lead to earlier treatment decisions and interventions. Additionally, the new guideline may help secure broader insurance coverage, ensuring that patients receive the comprehensive assessment needed to guide effective treatment strategies.
Read Announcement